Development of New Monoclonal Antibodies Recognizing Human Prostate-specific Membrane Antigen (PSMA)

Case ID:
C14329
Disclosure Date:
8/14/2016
Description:
Unmet Need
Prostate-specific membrane antigen (PSMA, also known as GCPII) is a validated target for prostate cancer imaging and therapy.  Macromolecular reagents, most notably monoclonal antibodies (mAbs), offer a viable alternative to small-molecule PSMA ligands for imaging and therapy.  However existing anti-PSMA antibodies have several drawbacks, including limited commercial availability, poorly defined epitopes, and lack of data on cross-reactivity towards GCPII paralogs and orthologs.

Technology Overview
The technology includes four novel murine monoclonal antibodies (mAbs) that recognize human PSMA.  One of these novel mAbs, 5D3, has approximately 10-fold higher affinity for PSMA than the clinically validated mAb J591 and therefore is a prime candidate for the development of next-generation theranostic agents targeting PSMA.

Stage of Development 
mAbs characterized by western-blot, ELISA, IHC, immunocytochemistry, flow cytometry, immunofluorescence and in a cell-based model.  Data from a mouse xenograft model demonstrate feasibility for in vivo imaging.   
Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Development of New Monoclonal Antibodies Recognizing Human Prostate-specific Membrane Antigen (PSMA) PRO: Provisional United States 62/442,482 1/5/2017     Expired
Development of New Monoclonal Antibodies Recognizing Human Prostate-specific Membrane Antigen (PSMA) PCT: Patent Cooperation Treaty PCT PCT/US2018/012530   1/5/2018     Pending
Inventors:
Category(s):
For Information, Contact:
Jeanine Pennington
jpennin5@jhmi.edu
410-614-0300
Save This Technology:
2017 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum